DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer's proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.

DNAPrint Genomics, Inc. trades as DNAG on OTC. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $2.43M of revenue and -$12.35M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

DNAPrint Genomics, Inc. can be compared against peers such as AVAX Technologies, Inc., Braxia Scientific Corp., Interpharm Holdings, Inc., Jack Nathan Medical Corp., LadRx Corporation, Manhattan Scientifics, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $12,892, beta of 1.53, and return on equity of +332.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

DNAG currently shows total debt of $7.28M and beta of 1.53. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: http://www.dnaprint.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.